AIFD: Turkey OTC Legislation Must Meet Stakeholders’ Needs
This article was originally published in PharmAsia News
Executive Summary
Turkey’s reimbursed over-the-counter (OTC) market has reached around TRY2.5 billion ($1.19 billion). But as the dynamic and rapidly growing sector attracts pharmaceutical companies, its development is also complicating discussions about enacting new legislation for OTCs. Answering questions from PharmAsia News, Osman Kara of the Association of Research Based Pharmaceutical Companies (AIFD) calls for new legislation that addresses the concerns of all stakeholders.